Nuvolone, Mario http://orcid.org/0000-0001-8334-1684
Nevone, Alice http://orcid.org/0000-0002-7724-1043
Merlini, Giampaolo http://orcid.org/0000-0001-7680-3254
Funding for this research was provided by:
Ministero della Salute (GR-2018-12368387)
Fondazione Cariplo (#2018-0257)
Associazione Italiana per la Ricerca sul Cancro (Accelerator Award Program, Accelerator Award Program)
Università degli Studi di Pavia
Article History
Accepted: 7 August 2022
First Online: 12 September 2022
Declarations
:
: Open access funding provided by Università degli Studi di Pavia within the CRUI-CARE Agreement. This work was supported by grants from the Italian Ministry of Health (Ricerca Finalizzata, Grant number GR-2018-12368387) [to MN], CARIPLO Foundation (Grant #2018-0257) [to MN], Cancer Research UK [C355/A26819], FC AECC and AIRC under the Accelerator Award Program [to MN, GM].
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Mario Nuvolone is an inventor on a patent application unrelated to this work, and received research funding from Oncopeptides and Gate Bioscience. Alice Nevone declares no conflicts of interest. Giampaolo Merlini is a member of the Advisory Board of Janssen and Pfizer.
: GM conceived the study and drafted the initial version of the manuscript. All authors contributed to the literature research, data analysis, and writing. All authors read and approved the final manuscript.